Specialty Pharmacy

Costs grow for people with oral cavity and pharyngeal cancers based on demographics, co-existing illnesses, and treatment selection.

Biological mechanisms of breast milk may have preventative effect.

Nivolumab extends life by 3.2 months compared with chemotherapy.

National Association of Specialty Pharmacy (NASP) Executive Director James E. Smeeding, RPh, MBA, discusses the National Association for Specialty Pharmacy and their efforts to enhance the specialty space.

The FDA has granted breakthrough therapy designation to Genzyme's olipudase alfa enzyme replacement treatment for nonneurological manifestations of acid sphingomyelinase deficiency.

Health-system pharmacists are facing inevitable challenges to ethics and autonomy embedded in their evolving everyday practice.

Could changes in the physical attributes of generic drugs affect patient adherence? The FDA seeks to survey pharmacists and patients to find out.

Nivolumab has increased the survival rate in patients with low grade adverse events.

A look back at the top stories of the week on Specialty Pharmacy Times.

Top news of the week from the annual meeting of the American Society of Clinical Oncology.

Drug found to improve physical function.

Combination therapy with AKT inhibitors shows promise.

Operations halted after vials of albumin were found to have fungal contamination.

Marketplace users less likely to use most medication classes except for hepatitis C and HIV.

David Lassen, chief clinical officer at Prime Therapeutics, discusses methods to overcome the impact of increasingly high copays on patient adherence.

Chemotherapy combination extends progression-free survival over standard chemotherapy.

Research seeks to determine how cancer cells avoid chemotherapy.

High level of benefit found in Gazyva compared with bendamustine.

Test projects which agent will work best against particular tumors.

Pharmacy-based transition of care (TOC) interventions that include post-discharge medication therapy management (MTM) services are strongly correlated with reduced hospital readmissions.

The FDA has granted priority review to Merck's pembrolizumab (Keytruda) for the treatment of advanced non-small cell lung cancer (NSCLC).

Melanoma incidence increased 250% in children, adolescents and young adults since 1973.

Gene mutations found in some patients provide hope for new and existing treatments.

Patients with a fast resting heart rate may have a higher risk of developing type 2 diabetes.

Predictive model uses routine lab values and machine learning method.

Therapy disrupts signals that fuel inflammation.

Amy Grogg, PharmD, senior vice president of Strategy and Commercialization at AmerisourceBergen Specialty Group discusses how the relationship between manufacturers, providers, and specialty pharmacies can be improved.

Merck is seeking FDA approval for its once-daily, single-tablet grazoprevir/elbasvir combination for the treatment of adult patients with chronic hepatitis C virus (HCV) genotypes 1, 4, or 6 infection.